Despite advances in our understanding of fertility, implantation failure remains a significant problem for both spontaneous and assisted pregnancies. Most research efforts concerning the process of implantation are embryo-centric, with a dearth of studies on endometrial factors. Currently, there are no practical and effective diagnostic tools available to precisely predict endometrial receptivity. Transcriptomics, a field based on microarray technology, has a number of procedures for clinical applications, although the functional relevance of most identified genes remains unclear. Importantly, RNA sequencing will further improve the precision and broaden the clinical use of the transcriptome by detecting previously undiscovered genes, which could be used to further our understanding of endometrial receptivity. In this review, potential biomarkers based on endometrium gene expression profiles of human endometrial receptivity were described and compared in natural and stimulated cycles toward discovering future prospects for personalized medical approaches. The intent of this synthesis is to provide researchers, doctors, and clinicians in the field with a better understanding of endometrium receptivity, promote further study in the transcriptome in embryo implantation, and ultimately, improve pregnancy outcome.
Introduction
Successful implantation is critical for establishing an ongoing pregnancy. Despite advances in our understanding of fertility, implantation failure remains a significant problem for both spontaneous and assisted pregnancies [1] . Implantation occurs when a free-floating mature blastocyst attaches to the endometrium, invades the stroma, and establishes the placenta. For this process to be successful, the endometrium must be in a receptive state [2] . This specific period of receptivity, which is regulated by a combination of ovarian steroid hormones and genetic factors, is known as the window of implantation (WOI), lasting 5 to 6 days after endogenous/exogenous progesterone increase [3] .
The most studied factor in the implantation triad is the embryo itself, although the endometrial factor has also been studied since the 1970s when the original "gold standard" method for endometrial status assessment first appeared [4] . However, the Mirkin et al. [20] Talbi et al. [21] Díaz-Gimeno et al. [22] Hu et al. [23] Cuevas et al. [24] Sigurgeirss on et al. [25] Secreted accuracy, reproducibility, and clinical utility of the Noyes dating criteria have been repeatedly questioned in retrospective [5, 6] , prospective [7, 8] , and randomized clinical trials [9, 10] concluding that histological endometrial dating does not provide useful clinical information. Through exploitation of multiple modalities of endometrial assessment in both normal and abnormal endometrium, methods, such as uterine secretions [11] , immunohistochemistry [12] , DNA microarrays [13, 14] , microRNA studies [15, 16] , and proteomic analysis [17] , have added to the complexity of our understanding of endometrial receptivity. Unfortunately, no effective diagnostic tools are available to predict endometrial receptivity in a precise manner, providing opportunities for personalized medical approaches to improve clinical success.
Here we review recent findings pertaining to new insights on endometrial receptivity derived by transcriptomic technologies toward identifying putative biomarkers of endometrial receptivity and their predictive value in forecasting pregnancy outcome during in vitro fertilization (IVF) treatment.
Natural cycles
Many global transcriptomic studies of human endometrium have been published in the past years, providing considerable information on the likely pattern of expression in receptive endometrium. Altmäe et al. [18] summarized a comprehensive review of omics studies in human endometrium and discovered that the number of genes identified in more than one study as potential biomarkers in endometrial physiology and pathophysiology has remained small, while any given study yields numerous candidate genes to explore. Some studies have reported modifications in gene expression profiles associated with transition of the human endometrium from a pre-receptive to a receptive stage [19] [20] [21] [22] [23] [24] [25] . However, only two genes were common to six of the seven largest studies (Table 1) : secreted phosphoprotein 1 (SPP1, previously known as osteopontin) and interleukin 15 (IL15). SPP1 is a glycoprotein involved in cellular adhesion and migration. It is the only factor identified that is common to most reported endometrial receptivity gene sets [26, 27] , and it is reported to be an essential mediator of implantation and receptivity in humans [28] . IL15 appears as a potential biomarker for the local preconception environment and its equilibrium [29] . Other studies that analyzed whole-genome gene expression during different menstrual cycle phases have been published. Although a definitive transcriptomic signature remains far from clear, SPP1 was consistently upregulated in all studies, and important enzymes and molecules involved in lipid metabolism, immune response, cell cycle regulation, and ion binding were identified in endometrial tissues at different receptivity stages [30] [31] [32] [33] . In addition, three genes were common to five studies (Table 1) : serpin family G member [SERP-ING1, previously known as serpin peptidase inhibitor, clade G (C1 inhibitor), member 1] is involved in the complement and coagulation cascade pathways [34] ; complement component 4 binding protein alpha (C4BPA) may provide a protective role to the embryo where increased expression of an inhibitor of complement system activation can reduce the chance of a misdirected complement attack to the embryo (considered a semiallograft) [35] ; and dickkopf WNT signaling pathway inhibitor 1 [DKK1, previously known as dickkopf (Xenopus laevis) homolog 1] has important roles in endometrial receptivity and early pregnancy, which includes regulation of endometrial cell proliferation and decidualization [36] . Noteworthily, considering the conserved role of these genes in endometrial receptivity, they are also upregulated in other nonprimate species during preimplantation [37] . Thus, these findings indicate that accurate endometrial cataloguing at different cycle stages, based on endometrial tissue transcriptomic profiles, may be possible despite varying results in the literature. Admittedly, 140 additional transcripts, which were either increased or decreased in pregnant endometrium, were identified, considerably expanding the set of genes differentially expressed in bovine endometrium at the preimplantation stage [38] . The possible reasons for disparities among these studies [19] [20] [21] [22] [23] [24] [25] include (1) the type of DNA detection method [e.g. DNA microarray, RNA-sequencing (RNA-seq) assay]; (2) fold-change thresholds; (3) applied strategies for data processing and a lack of consistent standards for data presentation; (4) number of samples from patients (ranged between 8 and 20 samples); (5) patient age (ranged between 22 and 44 years); and (6) sampling time during the cycle [luteinizing hormone (LH) + 1/5 to LH + 7/8] ( Table 2 ). Another important reason that illustrates these disparities is the recruited population, which may be fertile volunteers for an egg donation program 
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Downloaded from https://academic.oup.com/biolreprod/article-abstract/98/4/440/4819284 by OUP site access user on 08 October 2018 [20, [22] [23] [24] , normal pelvic women [19] , or normoovulatory women without gynecological diseases [21] (Table 2 ). In addition, the different timing of sample collection may be a particularly important factor contributing to the observed discrepancies among studies. Talbi et al. [21] revealed that 1190 genes and expressed sequence tags were significantly upregulated and 1027 were significantly downregulated through comparisons between late-secretory endometrium (LSE) and mid-secretory endometrium (MSE). Upregulated genes derived from genome-wide analysis of LSE versus MSE reveal numerous biological processes, including cell motility, cell communication, cell adhesion to the matrix, cell-cell signaling, apoptosis, proteolysis of cytoskeletal and extracellular matrix proteins, hemostasis, vasoconstriction, immune response, response to wounding and chemical substances, chemotaxis, and wound healing. Among the downregulated processes identified from LSE versus MSE are cell motility, migration, and adhesion; negative regulation of monocyte, osteoclast, and myeloid blood cell differentiation; ion homeostasis; cellular proliferation; metabolism of sugars, amino acids, steroid hormones, lipids, and fatty acids; and molecules needed for DNA synthesis. In addition, there was a lack of consensus on the results obtained, which was also likely caused by variability in some of the parameters, such as whether samples were taken from the same or different patients, whether samples were pooled, or because of platform-to-platform or laboratory-to-laboratory differences ( Table 2) . Evans et al. [39] compared two distinct DNA microarray platforms, Affymetrix and Agilent, and found concordance in their results. Surely, one of the future tasks for transcriptome studies will be separate analyses of endometrial compartments, which will provide a better knowledge of endometrial physiology, the interactions between different cell types, and their regulatory processes. Despite differences among transcriptomic studies, they all agreed on the existence of a specific transcriptomic profile during the WOI. This characteristic profile indicates that a specific transcriptional process occurs to achieve a receptive phenotype, the gatekeeper of which is progesterone receptor activation [19] [20] [21] [22] [23] [24] [25] [26] 40] . In addition to microarrays, there is the emerging alternative of RNA-seq, a powerful tool in which all RNAs are sequenced and most genes being expressed can be revealed. Indeed, the number of genes differentially expressed from the pre-receptive to the receptive endometrial transition is extremely variable (from 107 to 3278 genes) in all seven studies evaluated [19] [20] [21] [22] [23] [24] [25] . Mirkin et al. [20] , Talbi et al. [21] , and Díaz-Gimeno et al. [22] demonstrated differentially expressed genes during the WOI from 107 to 3059 genes, including 45.8%-60.1% of upregulated and 39.9%-54.2% of downregulated genes in DNA microarrays. This signature profile was similar to those reported by other studies that show similar proportions of up-and downregulated genes in the receptive endometrium with RNA-seq (46.3%-49.9% of upregulated and 50.1%-53.7% of downregulated genes); however, the specific transcriptomic profiles of these studies included 2372-3287 genes [23, 25] . RNA-seq technology detects more exons and alternative splicing events than microarrays as it is entirely independent of prior knowledge. Microarrays fail to pick up approximately 25% of genes with low expression, but such low abundance transcripts are detected in RNA-seq reads. Nevertheless, although it is true that RNA-seq is independent of prior knowledge, biological analysis of the data is not. RNA-seq analyses of human endometrium in healthy and disease states are required [18, 41] . Recently, with the aid of DNA detection methods, several approaches have been used to determine genes involved in uterine receptivity by assessing the endometrium under different physiological, pathological, or interventional conditions [42] .
All previous transcriptomic studies focusing on endometrial receptivity have generated extensive gene lists with known and unknown potential roles in this critical process. Hu et al. [23] found it notable that four genes, namely oviductal glycoprotein 1 (OVGP1), melanocortin 2 receptor accessory protein 2 (MRAP2), zinc finger CCHC-type containing 12 (ZCCHC12), and huntingtin-associated protein 1 (HAP1), found to be expressed in other tissues, were first identified to be differently expressed in prereceptive and receptive endometria. Saint-Dizier et al. [43] suggested that cOVGP1 expression in oviducts was estrogen-dependent. The high level of cOVGP1 expression in the oviduct at the time and place of oocyte maturation and fertilization indicates that this glycoprotein was intimately involved in these events. MRAP2 is predominantly expressed in the hypothalamus and adrenal gland, and previous studies have demonstrated its involvement in obesity in both humans and mice [44] . Mouse Zcchc12 (also known as Sizn1) is localized on the X chromosome. This gene serves as a transcriptional coactivator in the bone morphogenic protein signaling pathway. Human ZCCHC12 shares 74% sequence identity with that of Zcchc12 in mouse. Variants of ZCCHC12 have been associated with disease in humans [45] . Wang et al. [46] indicated that ZCCHC12 has important biological functions and that ZCCHC12 acts as a metastasis-related oncogene in papillary thyroid cancer. HAP1, the first protein associated with huntingtin (HTT), is specifically expressed in human brain tissue and is involved in Huntington disease pathogenesis [47] . Because a previous study has shown that HAP1 is related with vesicular transport [48] , HAP1 upregulation may adjust the secretion of macromolecules into the uterine lumen. Further study of these genes is needed to improve our knowledge of the novel functions of these "old genes" in modulating endometrial receptivity.
Since evidence of an endometrial gene expression profile accumulated from investigations in the past decade suggests that it is possible to accurately catalog and diagnose the human endometrial cycle and specifically, its receptive status based on its transcriptomic profile [19] [20] [21] [22] [23] [24] [25] 49] , Díaz-Gimeno et al. [50] developed a molecular diagnostic tool based on the specific transcriptomic signature. The endometrial receptivity array (ERA) consists of a customized array of 238 differentially expressed genes coupled to a computational predictor that identifies endometrial samples within the WOI regardless of their histological appearance. The ERA molecular tool was more accurate with higher reproducibility for endometrial dating, with a Kappa index of 0.922 (0.815-1.000) compared to classic histological methods that yielded values of 0.618 (0.446-0.791) and 0.685 (0.545-0.824) for each pathologist, respectively. Analyzing the lists of differentially expressed genes from previously published expression profiling studies, Altmäe et al. [51] performed a meta-analysis of endometrial receptivity-associated genes on 164 endometrial samples (76 from prereceptive and 88 from mid-secretory, receptive phase endometria) using a robust rank aggregation (RRA) method, and established a meta-signature of receptive endometrium with 57 genes as putative receptivity biomarkers. The commercial transcriptomebased endometrial receptivity diagnostic tool ERA shares 47 genes in common with this identified meta-signature. Furthermore, validation of the meta-signature of these genes in two different sample sets of healthy fertile women in mid-secretory versus early secretory endometria using up-to-date transcriptome analysis by RNA-seq confirmed 39 meta-signature genes. However, ERA identified 134 genes that were specific to the receptivity gene expression signature, excluding more than 3000 genes in other studies [19] [20] [21] [22] [23] [24] [25] , a finding which illustrates the difficulty of confirming a universally receptive signature for clinical applications.
Stimulated cycles
Using transcriptomic technology in human endometrial biopsy samples, several studies reported that modifications related to the gene expression profile were associated with transition of the human endometrium from a pre-receptive (early secretory phase) to a receptive (mid-secretory phase) state during a natural cycle [19] [20] [21] [22] [23] [24] [25] . However, Horcajadas et al. [52] suggested that controlled ovarian stimulation (COS) regimens may have a negative impact on endometrial receptivity compared to natural cycles. Diaz-Gimeno et al. analyzed comparisons of gene expression from the same patients (n = 21) between natural and stimulated cycles, and revealed that endometrial profiles were associated either with a moderately altered receptivity in most cases (86%) or a strongly altered receptivity during the COS protocol in a few cases (14%). In natural cycles compared to stimulated cycles, neonatal lethal factor 2 (NLF2) was increased by a factor of 12.6 compared to a factor of 2, prokineticin 1 (PROK1) was increased by a factor of 10.2 compared to that of 7.8, microfibril associated protein 5 (MFAP5) was increased by a factor of 37 compared to a factor of 11.5, and laminin subunit beta 3 (LAMB3) was increased by a factor of 20.4 compared to that of 11.1y [53] . These comparative findings are invaluable as it can open new perspectives, particularly in patients with multiple implantation failures.
Progesterone under controlled ovarian stimulation cycles
The impact of premature serum progesterone elevation at the end of the follicular phase under COS cycles for IVF remains unclear. Although some studies reported lower pregnancy rates in patients with a high progesterone concentration on the day of human chorionic gonadotropin (hCG) administration [54] [55] [56] , accelerated endometrial maturation following COS has been clearly demonstrated by histological dating on the day of oocyte retrieval [57, 58] and not during the implantation window [59] . To some extent, whether a high serum progesterone level is the reason that endometrial receptivity is impaired in patients is debatable. In addition, very few studies have assessed the impact of serum progesterone elevation on the endometrial gene expression profile during the implantation window. The influence of elevated progesterone levels on the endometrial gene expression pattern was also analyzed by Labarta et al. [59] comparing endometrial dating and endometrium gene expression pattern during the WOI in 12 healthy oocyte donors undergoing COS with pituitary suppression by either gonadotrophin-releasing hormone (GnRH) agonists or antagonists, and recombinant follicle stimulating hormone (rFSH). Six patients had progesterone levels above and six patients had levels below the threshold of 1.5 ng/mL. Out of 370 genes, 140 were dysregulated by more than twofold in women with high serum progesterone levels, and a large number of those genes represent biological processes, such as cell adhesion, immune system, and organ development. Therefore, dysregulation of those genes could affect the endometrium and the implantation process [59, 60] . Haouzi et al. also reported that the gene expression profiles of the endometrial shift from the prereceptive to the receptive secretory stage are altered in patients with high serum progesterone concentration ([P]) on the day of hCG administration compared to those found in patients with normal [P] . In their study, they individually compared the endometrial profile shift between the prereceptive (days hCG + 2) and receptive secretory stages (days hCG + 5) in patients with normal (<1.5 ng/mL) and high (>1.5 ng/mL) serum progesterone levels on the day of hCG administration. Using the detection call and the variation coefficient for an initial selection of genes expressed in the hCG + 2 and hCG + 5 endometrium samples, 6084 and 6130 genes were identified in the normal and high [P] groups, respectively. Next, significance analysis of microarrays (SAM from Stanford University) analysis of the microarray data was performed, and identified 1477 and 233 genes that were differentially modulated between the two endometrial stages in the normal and high [P] group, respectively. This finding suggests that endometrial maturation is accelerated during the early secretory phase in the high [P] group. Furthermore, the lists of those genes that were differentially expressed between the two stages in the endometrium samples from the high (n = 233 genes) and normal (n = 1477 genes) [P] groups were crossintersected, and it was discovered that 212 genes were exclusively modulated in the high [P] group. Among them, over 50 genes were involved in the cell cycle (P = 2.22E-11-2.41E-02], including several members of the cell division cycle family and kinesins; 75% of these genes were downregulated. This finding was confirmed by functional annotation analysis that revealed many of the downregulated genes are involved in cell cycle functions [61] . Previous studies [57, 58] showed an advanced endometrial maturation (2-4 days) based on histological dating on the day of oocyte retrieval (hCG + 2); however, this effect was irrespective of serum [P] on the day of hCG administration.
Moreover, it is known that progesterone may inhibit normal endometrial proliferation [62] . The largest meta-analysis published on this topic included more than 60 000 cycles, and the data were stratified according to different progesterone thresholds. Progesterone levels of 0.8 ng/mL and above were already associated with a significantly negative correlation between progesterone elevation and pregnancy achievement [63] , however, for the first time, Young et al. [64] provided direct evidence that abnormally low [P] results in delayed endometrial development and abnormal patterns of gene expression in a case-control experimental trial, during which 46 healthy young female volunteers (age 19-34 years) underwent a single modeled endometrial cycle after GnRH downregulation or monitored in natural cycles. In addition, abnormalities in gene expression occurred at higher subphysiological [P] without a change in histology, indicating a functional-morphological disassociation. The expression of some endometrial receptivity-associated genes appeared multiphasic, with a peak or nadir of mean or median expression levels between the lowest and highest doses, a finding which suggests that sustained supraphysiological doses seen in assisted reproductive technology treatment cycles may not be optimal.
Many genes have a monophasic response to changes in [P], such as SPP1 and vanin 1 (VNN1), whose mean and median expression with 2.5 mg progesterone daily was similar to that found using 40 mg, although mean and median expression by polymerase chain reaction (PCR) appeared maximal with 10 mg. In contrast, expression of homeobox A10 (HOXA10) was distinctly multiphasic. From PCR analysis, compared to the level observed in women receiving 40 mg progesterone daily, HOXA10 expression decreased with daily administration of 10 mg, 5 mg, and 2.5 mg progesterone, with the lowest expression at a daily dose of 10 mg. The complex pattern of HOXA10 expression suggests the possibility that the actions of progesterone may need to be finely tuned to optimize endometrial receptivity. Strikingly, Young et al. [64] also observed that histological endometrial development proceeds normally even when [P] is well below that normally observed during the luteal phase of natural cycles. In other words, the influence of progesterone on cell proliferation may be dose dependent; however, premature progesterone elevation in the presence of normal LH levels and with administration of GnRH is not related to premature luteinization, but is caused by ovarian overstimulation [65] . Gonadotrophin-releasing hormone agonists and antagonists Nowadays, emerging evidence suggests that ovarian stimulation is associated with advancement of endometrial maturation irrespective of whether GnRH agonists or antagonists are used [65] . Mirkin et al. [66] and Simon et al. [67] analyzed the impact of standard and high doses of a GnRH antagonist compared to treatment with a GnRH agonist in COS cycles in two prospective and randomized studies. Mirkin et al. [66] investigated whether gene expression profiles differed in the endometrium during the putative window by comparing temporally matched natural cycles (n = 5, day 21 or LH + 8) to COH cycles accomplished with a long protocol using a GnRH agonist and rFSH with supplementation of the luteal phase with P4 (n = 3, day 21 or hCG + 9). In this specific comparison, and with a median falsepositive value less than 1, six genes (0.16% of genes expressed in all biopsies) were differentially expressed between groups. Of these genes, five were upregulated specifically, leukocyte Ig-like receptor (LILR), optineurin (OPTN), NME/NM23 nucleoside diphosphate kinase 2 (NME2), CD63 molecule (CD63), and charged multivesicular body protein 1A [CHMP1A; previously known as procollagen (type III) N-endopeptidase], while an enolase superfamily member 1 (ENOSF1; also known as rTS) was downregulated. They also investigated concordant genes during the WOI (hCG + 9) in COH cycles stimulated with either a GnRH agonist and rFSH supplemented with P4 (n = 3) or a GnRH antagonist and rFSH supplemented with P4 (n = 5), and found significant differences for 13 genes: major histocompatibility complex, class II, DM beta (HLA-DMB); major histocompatibility complex, class I, G (HLA-G); interleukin 10 (IL10); phosphorylase kinase regulatory subunit beta (PHKB); cytochrome c oxidase assembly homolog (COX17); RAB1A, member RAS oncogene family (RAB1A); selenoprotein P (SELENOP); annexin A7 (ANXA7); sorting nexin 7 (SNX7); RAS related 2 (RRAS2); tumor suppressor candidate 3 (TUSC3); UDP-glucose pyrophosphorylase 2 (UGP2); and nuclear protein 1, transcriptional regulator (NUPR1), all of which were upregulated in the GnRH agonist group [64] . The endometrial genomic profile of a natural cycle was more closely mimicked in women undergoing COS after daily treatment with a GnRH antagonist compared to those treated with a GnRH agonist, thus highlighting the need for further efforts to optimize COS protocols. Haouzi et al. [53] adopted a new study design comparing the early and mid-secretory phases during a natural and a stimulated cycle with the same patients. In natural and stimulated cycles, the majority of genes modulated during endometrial receptivity were upregulated (93% in the natural cycle compared to 78% in the stimulated cycle). Among those upregulated genes of endometrial receptivity in stimulated cycles, only 46% were common to those found in the natural cycle, a finding which suggests that either the duration or FSH dose in gonadotrophin treatment under COS cycles leads to the transcriptional activation observed in other genes that are not involved in physiological endometrium receptivity. Furthermore, major differences in biological functions known to be involved in the implantation process, such as the TGFβ signaling pathway [68] , the complement and coagulation cascades, and the leukocyte transendothelial migration [69] [70] [71] [72] , were observed between the natural and stimulated cycles. The upregulation of genes involved in these signaling pathways was discovered in natural cycles, and was lacking in stimulated cycles. The discrepancies between these studies analyzing the effects of stimulation protocols on endometrial receptivity may have several explanations: (1) differences in the day of endometrial biopsy sampling, (2) different patient profiles, (3) different COS protocols, and (4) inadequate numbers of endometrial samples were studied.
Tamoxifen
Multiple studies have focused on clomiphene citrate and tamoxifen for ovulation induction. However, it was not until 2011 that the first prospective randomized trial carried out a comparison between raloxifene and clomiphene citrate for ovulation induction [73] . Chen et al. [74] adopted a new study design evaluating normal saline solution (n = 12), raloxifene (n = 12), and clomiphene citrate (n = 12) groups. They compared the effects of raloxifene and clomiphene citrate, which were used to induce ovulation, on endometrial receptivity markers in mice during the WOI, including HOXA10, integrin subunit beta 3 (ITGB3), LIF, interleukin 6 family cytokine (LIF), and pinopodes, a feature that few studies have reported. HOXA10 regulates proliferation, differentiation, and decidualization of the endometrium, playing an important role in endometrial receptivity and embryo implantation. Expression of HOXA10 increases drastically in the midluteal phase of the menstrual cycle corresponding to the time of implantation [75] . They also found that HOXA10, ITGB3, LIF, and pinopodes were present in the endometrium of mature female mice compared to mice undergoing natural cycles and raloxifene treatment, and that administration of clomiphene citrate significantly reduced measures of these four markers. However, the molecular mechanisms underlying the effect of raloxifene on human endometrial receptivity and its safety on the embryo need to be further explored.
Conclusions
The number of available biomarkers for assessment of endometrial receptivity is increasing dramatically, but no effective diagnostic tools are yet available to precisely predict endometrial receptivity. To date, transcriptomic data can provide a panel of genes as putative biomarkers for assessment of the receptive status of the human endometrium. In fact, the use of omics tools to explore endometrial receptivity contributes to improvements in the pregnancy success rate. However, only one gene SPP1 (osteopontin), a glycoprotein involved in cellular adhesion and migration, was common to all studies reviewed (Table 1) . Furthermore, SPP1 is the only common factor to all reported endometrial receptivity gene sets [26, 27] , and it is an essential mediator of implantation and receptivity in humans [28] . Gene profiles of endometrial receptivity under natural and stimulated cycles are significantly different, which may be related to the impact of premature serum progesterone elevation at the end of the follicular phase under a COS cycle. In addition, the establishment of reliable biomarkers of endometrial receptivity will likely require a re-examination of how these studies should be performed and what patients should be included. New high-throughput technologies and associated computational analyses need to evolve and develop further before they can be considered cutting-edge technologies for clinical applications. Transcriptomics, based on microarray technology, currently has a number of procedures enabling its clinical use, although the functional relevance of expression changes in many genes remains unclear and challenging to interpret. Nevertheless, we are on the cusp of a new era in transcriptomics. RNA-seq technology is improving the scope and depth of our knowledge of the transcriptome by detecting previously undiscovered genes, and could be more broadly adopted to elucidate more about endometrial receptivity. Not long in the future, transcriptomic tools will be used independently or in combination with other classical methods such as ultrasound to better understand the receptive status of the endometrium and improve pregnancy outcomes.
